

Duchenne Muscular Dystrophy (DMD)

**Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of
RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy**

Trial Status
Completed

Trial Runs In
13 Countries

Trial Identifier
NCT03039686 2016-001654-18
CN001-016

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).

Hoffmann-La Roche
Sponsor

Phase 2/Phase 3
Phase

NCT03039686 2016-001654-18 CN001-016
Trial Identifiers

Eligibility Criteria:

Gender
Male

Age
≥6 Years & ≤ 11 Years

Healthy Volunteers
No
